Ilya Pharma, a clinical stage immunotherapy company, has made a strategic investment in its supply chain to facilitate development of its ILP pipeline of skin and mucosal immunotherapy drug candidates by acquiring one of its long-term partners, Nordic Bioanalysis. Founded in 2010, Nordic Bioanalysis have established a strong reputation both in the Nordics and internationally as experts in bioanalytical development and validation for pharmaceuticals, classic small molecules and biologics including antibodies as well as Advanced Therapy Medicinal Products (ATMPs).
